By Dirk Brinckman Chief Compliance Officer, Johnson & Johnson Chair, IFPMA Ethics and Business Integrity Committee Chair, ...

IFPMA submitted a statement at the start of the 17th meeting of the Conference of the Parties to the Convention on Biological ...

On 13 October 2026, on the occasion of the adoption of the Political Declaration on Pandemic Prevention, Preparedness, and ...

IFPMA submitted a statement at the start of the 17th meeting of the Conference of the Parties to the Convention on Biological Diversity (CBD COP17), which takes place 19-30 October in Yerevan, Armenia ...

This compendium of facts and figures aims to provide a snapshot of the contribution of the pharmaceutical industry.

This event has now passed. To browse our upcoming events click here. Scientific progress can only realize its full potential when accompanied by public confidence in the institutions, expertise and ...

The innovative biopharmaceutical industry, having developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for more equitable ...

As a Standing Observer of ICH, IFPMA along with other ICH Members and Observers, has an important role in promoting global convergence toward ICH regulatory standards and their harmonized ...

Our Code of Practice was first drawn up in 1981, and it was the first one of its kind for any sector. Initially, correct information on the effects and side effects of medicines were at the core of ...

17 October 2023, Geneva – A draft of the World Health Organization (WHO) Intergovernmental Negotiating Body’s (INB) international instrument on pandemic prevention, preparedness and response, commonly ...